

#154

COMPLETE

Collector: Web Link 1 (Web Link)
Started: Wednesday, October 08, 2025 8:04:34 AM
Last Modified: Wednesday, October 08, 2025 8:32:44 AM
Time Spent: 00:28:09
IP Address: 70.67.237.0

Page 2: Part 1

Q1

Title of activity

Food allergy treatment RAFT debate

Q2

Date of activity

October 18th

Q3

Speaker

What is your role in the CPD activity? (Select all that apply)

Q4

Combination - Community and Academic

What's your practice type?

Q5

Please indicate:

I HAVE a relationship with a for-profit and/or a not-for-profit organization to disclose.If so, please indicate below (questions 5 to 10) the organization(s) with which you have/had a relationship over the previous two years and briefly describe the nature of that relationship.

Q6

Any direct financial payments including receipt of honoraria

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

ALK

Description of relationship(s)

Speaking honorarium

Q7

Membership on advisory boards or speakers' bureaus

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

Alladapt, ALK, BioCryst, Celltrion

Description of relationship(s)

Advisory boards

Q8

Funded grants or clinical trials

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)

None

Q9

Patents on a drug, product or device

Name of FOR PROFIT and/or NOT-FOR PROFIT organization(s)
(separate with commas)

None

Q10

All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity

Name of FOR PROFIT and/or NOT-FOR PROFIT organization(s)
(separate with commas)

None

Page 3: Part 2: To be completed by presenters only

Q11

I intend to use trade names during my presentation. Note: Only generic names should be used whenever possible. If trade names are used, they should be accompanied by the generic name.

Yes (please list - Only generic names should be used whenever possible. If trade names are used, they should be accompanied by the generic name) :
Xolair/Omlyclo (omalizumab)- may come up re discussion of cost of therapy using omalizumab in the RAFT debate

Q12

I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication). Note: You must declare all off-label use to the audience during your presentation.

Yes (please provide a brief description or rationale):
Use of omalizumab with OIT will come up during debate (off label, currently being studied in OUTmatch trial). Of note, while there is a perceived conflict here, I'll actually be arguing AGAINST this off-label use by looking pointing out costs of this potential therapeutic approach.

Q13

Yes

If you answered "Yes" to the previous question, are the medications recommended manufactured by companies you have received funding from?

Q14

Yes

I acknowledge that the National Standard requires that any description of therapeutic options utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.

Page 4: Part 3 (Anonymous & Optional): Equity, Diversity and Inclusion (EDI)

Q15

Yes

I confirm that I've completed the EDI Survey linked above

Page 5: PART 4: Acknowledgement and signature (for all)

Q16

First Name:

Scott

Q17

Last Name:

Cameron

Q18

He/Him

Gender Pronouns - How would you like us to address you?

Q19

Please review and check the items below.

I confirm that the above information is accurate and complete.

,

I understand that this information may be publicly available
